Unveiling the Economic Burden of Untreated Mental Illness

By HEOR Staff Writer

October 25, 2023

A Better Understanding of the Financial Burden

In the United States, roughly one in five people will struggle with some form of mental illness in any given year; yet, less than half of those people will obtain the appropriate care. The COVID-19 pandemic has further compounded the absence of effective mental health services, leaving millions of people with unmet treatment needs. Untreated mental illness has consequences that reach beyond the person who suffers from it. These consequences include a decrease in the individual’s quality of life, productivity, and overall health. They may even result in work difficulties or engagement with the legal system. Because of this, individuals, families, and society as a whole are forced to shoulder a tremendous amount of additional financial strain.

The Requirement for Detailed Information

Policymakers need comprehensive data on the financial consequences of untreated mental illness to address this issue effectively. Previous research has explored the financial impact of various mental diseases. However, no study has fully examined the costs of untreated disease. Health insurers, governments, and employers need this data. It helps them understand the total economic burden of untreated mental illness. It also shows the potential cost savings from improving access to and delivering mental health care. 

A Case Study: Indiana

A recent study was conducted in Indiana with the purpose of estimating the economic impact of untreated mental illness in the state. The findings of this study will be used to inform legislation and programs that are designed to address this issue. The research presented a methodology at the societal level to evaluate both direct and indirect costs associated with untreated mental diseases. The research estimated the individual, family, workplace, and community expenses associated with untreated mental disorders. The findings were shocking: it was predicted that Indiana bears a total annual economic burden of $4.2 billion due to untreated mental illness.

Taking Steps to Address the Problem

The importance of early detection, counseling, and access to mental health services and therapies is driven home by these findings. Not only could these approaches increase the productivity of individuals and minimise their need for social services, but they also had the potential to drastically cut the expenses associated with incarceration and homelessness. It has been argued that telehealth might be used as a viable means to improve access to therapy, and recent regulatory changes in Indiana have made it possible for Medicaid to compensate providers for providing telehealth services.

The Duty That Falls on Policymakers

Policymakers have an important part to play in removing obstacles to seeking and getting treatment, such as providing care that is sensitive to cultural norms and addressing the stigma that is associated with seeking therapy. They are able to secure improved long-term outcomes and overall cost savings for health care systems as well as society as a whole when they embrace a comprehensive strategy to recognising and resolving the economic burden of untreated mental illness. This is possible because of the comprehensive nature of the approach.

Reference url

Recent Posts

Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

By João L. Carapinha

December 17, 2025

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, ...
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggressive Prostate Cancer

By HEOR Staff Writer

December 16, 2025

AKEEGA BRCA2 Approval Ushers in Precision Era for mCSPC The AKEEGA BRCA2 approval by the U.S. Food and Drug Administration (FDA) on December 12, 2025, represents a breakthrough for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Johnson & Johnson...
Translational Medicine Portugal: Driving Collaborative Innovations in Healthcare

By João L. Carapinha

December 15, 2025

Spotlight on Translational Medicine in Portugal Translational medicine Portugal has gained international attention through the EATRIS (European Infrastructure for Translational Medicine) Spotlight program, coordinated by